Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor

[1]  C. Antonescu,et al.  Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras , 2019, Annals of surgery.

[2]  C. Raut,et al.  Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial , 2018, JAMA oncology.

[3]  K. Rosenzweig,et al.  Immortal Time Bias in Observational Studies of Time-to-Event Outcomes , 2018, Cancer control : journal of the Moffitt Cancer Center.

[4]  C. Antonescu,et al.  Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome , 2017, Annals of Surgical Oncology.

[5]  S. Hahn,et al.  Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach , 2017, British Journal of Cancer.

[6]  C. Antonescu,et al.  Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis , 2017, Annals of surgery.

[7]  E. Wardelmann,et al.  Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Yuhree Kim,et al.  Surgical management of advanced gastrointestinal stromal tumors: an international multi-institutional analysis of 158 patients. , 2014, Journal of the American College of Surgeons.

[9]  C. Antonescu,et al.  Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. van Coevorden,et al.  Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  S. Sleijfer,et al.  Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience , 2013, Annals of Surgical Oncology.

[12]  L. Sidéris,et al.  Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial , 2012, International journal of surgical oncology.

[13]  E. Wardelmann,et al.  Neoadjuvant treatment of locally advanced GIST: Results of APOLLON, a prospective, open label phase II study in KIT- or PDGFRA-positive tumors. , 2012 .

[14]  Aki Vehtari,et al.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.

[15]  G. Demetri,et al.  Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132 , 2012, Annals of Surgical Oncology.

[16]  Aki Vehtari,et al.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.

[17]  C. Antonescu,et al.  Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. , 2009, The Lancet. Oncology.

[18]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[19]  C. Antonescu,et al.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) , 2008, Cancer.

[20]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Antonescu,et al.  Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor , 2007, Annals of surgery.

[22]  K. Hunt,et al.  Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib , 2006, Annals of Surgical Oncology.

[23]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[24]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[25]  W. El-Rifai,et al.  Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. , 2002, Human pathology.

[26]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[27]  G. Demetri,et al.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 , 2009, Journal of surgical oncology.

[28]  J. Girones,et al.  Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. , 2007, European journal of cancer.

[29]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[30]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.